Navigation Links
Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe
Date:3/10/2009

However, Off-Label Use of Avastin Will Take Market Share Away from Lucentis from 2012 to 2017, According to a New Report from Decision Resources

WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual 17 percent growth in the age-related macular degeneration (AMD) market through 2012 will be driven primarily by expanding use of Genentech/Novartis Ophthalmics' Lucentis in Europe. However, off-label use of Genentech/Roche/Chugai's Avastin will take market share away from Lucentis from 2012 through 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Age-Related Macular Degeneration finds that near-term opportunity in wet AMD exists in the development of therapies that offer efficacy at least similar to that of Lucentis, along with advantages in dosing. However, because retinal specialists administer Lucentis less frequently (as needed) than its approved monthly dosing --which is the dosing used in clinical trials -- emerging therapies face high barriers in providing convincing evidence for dosing improvements over Lucentis.

Additionally, although experts have considered Regeneron/Bayer's aflibercept the most promising emerging therapy for wet AMD, recent clinical data has cast doubt on the agent's ability to demonstrate significant efficacy and/or dosing improvements over Lucentis. As a result, aflibercept will garner about 10 percent patient share in AMD in 2017 but its sales will fall short of blockbuster status because of strong competition from Lucentis and Avastin.

According to the report, the successful launch of therapies for dry AMD, which accounts for up to 95 percent of all cases of the disease, would address a critical unmet need and would revolutionize both the marketplace and management of AMD. However, such an event is not expected to occur between now and 2017.

"Overall growth of the AMD market for prescription therapies is driven by agents for the wet form of the disease, in particular, vascular endothelial growth factor inhibitors," said Decision Resources Analyst Irene Koulinska, M.D., Sc.D. "We estimate that sales of this drug class will grow at a rate of two percent annually between 2007 and 2017. This reflects, primarily, the patient share dynamics between the approved agent from this class, Lucentis, and its less expensive, off-label alternative, Avastin."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
2. NxStage to Present at the Cowen and Company 29th Annual Healthcare Conference
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
7. Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting
8. Stephen H. Friend, MD, PhD to Keynote at Defined Healths 9th Annual Therapeutic Insight Conference
9. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
10. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
11. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Global Stem Cells Group has announced ... treatment center in Quito, Ecuador, Feb. 24-March 6, 2016. The new facility will provide ... , Global Stem Cells Group CEO Benito Novas will host the event, which ...
(Date:2/12/2016)... , Feb. 12, 2016 Biocom, the association representing ... took a group of San Diego ... of its 2016 Precision Medicine Advocacy Fly-In. Biocom Fly-In participants ... and Drug Administration (FDA), the Centers for Medicare and Medicaid ... as San Diego U.S. Representatives Susan Davis and ...
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... 7-10, at the Georgia World Congress Center in Atlanta, Georgia, will include 848 ... These leading companies will be displaying products and services used by the ...
(Date:2/12/2016)...  BD (Becton, Dickinson and Company) (NYSE: BDX ... the launch of the BD CLiC™ System during the ... --> --> ... cost effective NGS library preparation with limited operator intervention. ... next generation sequencing (NGS) library prep instrument, engineered for ...
Breaking Biology Technology:
(Date:2/11/2016)...  According to new research from Acuity Market ... 200 fingerprint, iris, and eye-vein biometric smartphones have ... names. This includes market leaders Apple, Samsung, Huawei, ... that 600 million biometric smartphones are currently in ... Maxine Most , Acuity Market Intelligence ...
(Date:2/11/2016)... 11, 2016  Vigilant Solutions announces today that its license ... used by Lee,s Summit Police Department ... and arrest of a homicide suspect. Kansas ... around 65 square miles and is home to roughly 100,000 ... a single mobile license plate reader system and also leverages ...
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market ... iris recognition is more widely accepted for ... with both fingerprint and iris recognition technology ... user to avoid purchasing two individual biometrics ...
Breaking Biology News(10 mins):